A new study confirmed an elevated risk for myelodysplastic syndrome or acute myeloid leukemia (MDS/AML) after poly(ADP-ribose) polymerase (PARP) inhibitor therapy in women with ovarian cancer and ...

Combined treatment with a tyrosine kinase inhibitor and blinatumomab has converted Ph-positive ALL, once the most deadly hematologic cancer, to a disease with long-term survival of 75 to 80%.